Quadruple-vaxxed 60-year-old man tests positive for COVID second time in 2 months

59-year-old male got vaccinated with the first two doses of Pfizer/BioNTech COVID-19 vaccine in March 2021. He received the recommended initial (third dose) and 2nd (fourth dose) booster shots following the CDC guidelines. 

CDC strengthened its recommendation on the 1st booster shot for individuals who are 18 years and older in the end of November 2021, if they were 6 months after their initial Pfizer or Moderna series or 2 months after their initial J&J vaccine.

Following FDA’s regulatory action, on March 29 2022,external iconCDC updated its recommendations to allow all people over the age of 50 who received an initial booster dose at least 4 months ago to be eligible for another mRNA booster to increase their protection against severe disease from COVID-19. 
external icon, today, CDC is updating its recommendations to allow certain immunocompromised individuals and people over the age of 50 who received an initial booster dose at least 4 months ago to be eligible for another mRNA booster to increase their protection against severe disease from COVID-19. Separately and in addition, based on newly published data, adults who received a primary vaccine and b

The individual tested positive for COVID-19 for the first time at age 60, on August 15th 2022, and for the second time on September 24th 2022.  

In August he was experiencing very mild symptoms and started a course of Pfizer’s oral COVID-19 antiviral treatment, Paxlovid, while isolating and following all public health precautions. In September his COVID seemed to be asymptomatic. 

BA.5 was comprising over 80% of all variants detected by CDC in the US both times the individual was infected with the virus. In August, however, second leading variant was BA.4, the 3rd was BA.4.6 and the 4th was BA.2.12.1 while in the end of September 2nd most prevalent variant was BA.4.6 and the 3rd was rapidly gaining ground BF.7.

REFERENCES

https://twitter.com/AlbertBourla/status/1369734954498818052

https://twitter.com/AlbertBourla/status/1573765059540647936

https://www.pfizer.com/news/announcements/statement-pfizer-chairman-and-ceo-albert-bourla-testing-positive-covid-19

https://twitter.com/AlbertBourla/status/1559145992594784256

https://www.pfizer.com/news/announcements/statement-pfizer-chairman-and-ceo-albert-bourla-testing-positive-covid-19-0

https://covid.cdc.gov/covid-data-tracker/#variant-proportions

Comments

Post a Comment

Popular posts from this blog

A New Onset of Ulcerative Colitis post-2nd-breakthrough-COVID-19

Image
A 21-year-old non-smoking Caucasian male with a history of acute pancreatitis but no other medical issues or family history had two doses of the BNT162b2 mRNA COVID-19 vaccine.  Four months after the second dose he had his first episode of COVID-19. Although not hypoxic, he felt pretty unwell for a week, with a severe cough, fever, generalized body ache, headache, and loss of taste. He received the third dose of the vaccine two months after recovering from COVID. Nine months after the third dose, he had the second episode of COVID-19, during which he was mildly unwell for three days, recovered, and did not require any anti-viral medication or antibiotics. One week post the second episode of COVID-19, he developed diarrhea and abdominal pain. It then progressed to bloody diarrhea. Ulcerative colitis was diagnosed based on his clinical symptoms, biopsy changes, and the exclusion of other causes.  There are ten published case reports about the newly diagnosed ulcerative colitis associate
Read more

COVID in May

Image
Concerns about a potential resurgence of COVID-19 are mounting as summer 2024 approaches.  This is driven by several indicators, including social media posts, healthcare data, and wastewater surveillance across different regions. Our study findings corroborate this trend.  While many forecasters anticipate a surge, others expect a gradual increase through the end of May, and then a decline again around early June. Reports from social media suggest emerging clusters of COVID-19 in Texas, several Canadian provinces, the UK, and on cruises in northern regions such as a Norwegian cruise to Alaska.  Data from Alberta's Respiratory virus dashboard   (total weekly laboratory-confirmed COVID-19 cases) and wastewater surveillance in Calgary indicate an uptick in COVID-19 cases starting April 2024. The most recent statistics from Alberta Health reveal a significant increase in hospitalizations due to COVID-19, with 114 individuals currently hospitalized—an increase of more than 20% over two
Read more

Chronic SARS-CoV-2 Shedding

Image
Chronic viral shedding, a condition where the virus continues to be released from an individual's body long after the initial infection, has been observed in many infectious diseases, including COVID-19.  In such cases, individuals may remain asymptomatic or experience only mild symptoms while the virus persists. It remains detectable in repeated tests over an extended period and can still infect others even in nasal swab is negative (which happens quite often ). This was evident in our study.    Recent research by Conway et al. (2024) highlights the possibility of chronic SARS-CoV-2 infection, extending over several months and potentially years. Other studies have documented prolonged asymptomatic infections and extended viral shedding in moderate to severe beyond hospital discharge. Analysis of sequencing data on UK samples taken between 2 November 2020 and 15 August 2022 lead to estimates that 0.1–0.5% of infections may become persistent with typically rebounding high viral load
Read more